Despite no pCR being observed in the stage I cohort, neoadjuvant sintilimab plus chemotherapy could produce an MPR rate of 44.4% along with a tolerable safety profile and no disease progression, suggesting potential for conducting neoadjuvant immunotherapy and chemotherapy in EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.